Tumor News and Research

RSS

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

New study by bioethicists indicates patients give "broad endorsement" to iPSC research

In an early indication of lay opinions on research with induced pluripotent stem cells, which are stem cells made from skin or other tissues, a new study by bioethicists at Johns Hopkins University indicates that despite some ethical concerns, patients give the research "broad endorsement".

6 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Biologists at UC San Diego have discovered an effective strategy that could prevent the human immune system from rejecting the grafts derived from human embryonic stem cells, a major problem now limiting the development of human stem cell therapies.

3 Jan 2014

University of Utah discovers cellular mechanism that stops metastasis of breast cancer

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah discovered a cellular mechanism that drives the spread of breast cancer to other parts of the body (metastasis), as well as a therapy which blocks that mechanism. The research results were published online in the journal Cell Reports on January 2.

3 Jan 2014

Research confirms superior antitumor activity of novel anticancer agent FL118

A team led by Fengzhi Li, PhD, of Roswell Park Cancer Institute has reported significant new findings regarding the chemical structure of the novel anticancer agent FL118. The research, which included comparative analysis of the agent and several similar compounds, confirms the broad, superior antitumor activity of FL118 and suggests promising directions for further studies.

2 Jan 2014

FDA removes partial clinical hold on Cell Therapeutics' Tosedostat aminopeptidase inhibitor

Cell Therapeutics, Inc. (CTI) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.

2 Jan 2014

Innovative therapy offers new hope to breast cancer patients

A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.

2 Jan 2014

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Detect. Destroy. Remember. The mantra of the immune system's relentless campaign against infectious invaders and the body's own abnormal cells finally is applying to cancer in meaningful ways.

28 Dec 2013

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

Roughly 40 percent of all medications act on cells' G protein-coupled receptors (GPCRs). One of these receptors, beta 2 adrenergic receptor site (B2AR), naturally transforms between two base configurations; knowing the precise location of each of approximately 4,000 atoms is crucial for ensuring a snug fit between it and the drug.

28 Dec 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Cells' adaptations to low oxygen conditions inside tumors promote breast cancer's spread

Biologists at The Johns Hopkins University have discovered that low oxygen conditions, which often persist inside tumors, are sufficient to initiate a molecular chain of events that transforms breast cancer cells from being rigid and stationery to mobile and invasive.

27 Dec 2013

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Changes to LZTR1 gene predispose people to develop schwannomas

Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.

24 Dec 2013

Researchers report new gene delivery method that targets tumor blood vessels

Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene of interest that can be injected into the bloodstream and make its way to the right cells.

24 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Researchers start first cancer operation room with navigator

A team of researchers from Gregorio Marañón Hospital, the company GMV and the Universidad Carlos III de Madrid (UC3M) have started the first cancer operation room with a navigator. This image-guided system will allow for increased intraoperative radiotherapy safety.

22 Dec 2013

Tumor News and Research

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

New study by bioethicists indicates patients give "broad endorsement" to iPSC research

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Biologists discover effective strategy that could prevent immune system from rejecting grafts

University of Utah discovers cellular mechanism that stops metastasis of breast cancer

Research confirms superior antitumor activity of novel anticancer agent FL118

FDA removes partial clinical hold on Cell Therapeutics' Tosedostat aminopeptidase inhibitor

Innovative therapy offers new hope to breast cancer patients

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Cells' adaptations to low oxygen conditions inside tumors promote breast cancer's spread

Stem cell-based gene therapy shows long-term outcomes for treatment of genetic skin diseases

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Concordia Healthcare acquires Pinnacle Biologics

Changes to LZTR1 gene predispose people to develop schwannomas

Researchers report new gene delivery method that targets tumor blood vessels

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Researchers start first cancer operation room with navigator

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News